CIM
RARE icon

CIM Investment Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

CIM Investment Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,370
Closed -$214K – 312
2021
Q3 		$214K Hold
2,370
– – 0.07% 272
2021
Q2 		$226K Hold
2,370
– – 0.07% 269
2021
Q1 		$270K Buy
2,370
+853
+56% +$116K 0.09% 225
2020
Q4 		$210K Buy
+1,517
New +$180K 0.07% 268
2020
Q1 		– Sell
-4,780
Closed -$204K – 227
2019
Q4 		$204K Buy
+4,780
New +$197K 0.08% 209

Other funds holding RARE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

CIM Investment Management's RARE Position: Q4 2021 in Review

CIM Investment Management sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2021, closing a stake of 2,370 shares — an estimated $214K sold.

CIM Investment Management first reported a position in RARE in Q4 2019 and held it in 5 quarters. The position peaked at $270K in Q1 2021. 235 funds tracked by Wall St. Rank hold RARE as of Q4 2021.

  • CIM Investment Management reported no remaining Ultragenyx Pharmaceutical position as of Q4 2021 after selling out during the quarter.
  • CIM Investment Management sold 2,370 Ultragenyx Pharmaceutical shares in Q4 2021, an estimated $214K.
  • CIM Investment Management first reported a position in Ultragenyx Pharmaceutical in Q4 2019 and held it in 5 quarters.
  • CIM Investment Management's Ultragenyx Pharmaceutical position peaked at $270K in Q1 2021.
  • 235 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2021.

Based on CIM Investment Management's 13F filing for Q4 2021, filed 2 Feb 2022.